HeartBeam Inc. (NASDAQ: BEAT) has reported its second-quarter 2026 financial and operational results, showcasing significant advancements in its heart attack detection program, the development of a 12-lead ECG extended wear patch, and the initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, HeartBeam surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, a key milestone in validating its technology.
The company also completed a working prototype of its 12-lead ECG extended wear patch, a device designed to provide continuous cardiac monitoring. Commercial efforts have resulted in multiple agreements across four targeted U.S. geographies, with first orders shipped and initial patients onboarded. These developments underscore HeartBeam's commitment to bringing its innovative 3D ECG technology to market, which has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis software.
Financially, HeartBeam reported a net loss of $5 million, or $0.10 per share, for the second quarter, consistent with the prior year's loss. As of June 30, 2026, the company held $8.8 million in cash, cash equivalents, and restricted cash. The company expects full-year 2026 net operating cash outflow to be below $14 million, extending its cash runway into 2027. This financial stability is crucial as HeartBeam continues to invest in clinical trials and commercialization efforts.
The significance of these results lies in the potential of HeartBeam's technology to transform cardiac care. By enabling portable, cable-free ECG monitoring that synthesizes 3D signals into a standard 12-lead ECG, the company aims to provide actionable heart intelligence outside of medical facilities. This could lead to earlier detection of heart attacks and better management of cardiac conditions, ultimately improving patient outcomes and reducing healthcare costs.
HeartBeam's progress in its pilot studies and commercial rollout is a positive indicator for investors and the medical community. The completion of the ALIGN-ACS study enrollment and the advancement of the HEADSTART-ACS study are critical steps toward regulatory submissions and broader market adoption. The company's ability to secure commercial agreements and ship initial orders demonstrates tangible market traction.
For more information on HeartBeam's financial results and operational highlights, visit the full press release. To learn about the company's cleared indications for use, refer to HeartBeam's indications. Stay updated with the latest news on HeartBeam at their newsroom.
